NRF launches cybersecurity and synthetic biology consortiums to help companies tap new technologies

NRF launches cybersecurity and synthetic biology consortiums to help companies tap new technologies

By: 
Trinity Chua
20/09/16, 07:26 pm

SINGAPORE (Sept 20): Two new consortiums in cybersecurity and synthetic biology were launched today to spur collaborations between industry players, government agencies and research institutions.

The Singapore Cybersecurity Consortium (SGCC) and the Singapore Consortium for Synthetic Biology (SINERGY) are supported by the National Research Foundation. They will be hosted at the National University of Singapore.

“The idea of a consortium is to [bring together] our researchers who have received funding from us [NRF], and have created a portfolio of IPs and know-how through their research. The intent is to bring the industry [the companies that are interested in these technologies] now to them,” says CEO of NRF, Professor Low Teck Seng, at the opening of the Singapore Week of Innovation and TeCHnology (SWITCH).

Advertisement

Low says that most companies around the world are cutting down their R&D budget amid a tougher business environment.

Through the consortiums, companies can leverage on the expertise of the research institutions to bring new technologies to market in a more efficient manner.

Companies that “leverage research from the consortiums for collaborative projects with researchers” can also apply for co-funding from the NRF.

NRF has invested $42 million in seven research projects under the National Cybersecurity R&D Programme and $34 million in eight synthetic biology related R&D projects so far. The consortiums will build on these projects, and seek opportunities to bring them to market.

There are currently 14 industry players in the cybersecurity consortium, including StarHub, ST Electronics, Singapore Telecommunications, PwC Singapore and Standard Chartered Bank Singapore. The synthetic biology consortium has more than 10 companies as members, including GlaxoSmithKline and Wilmar International. Consortium members will have access to a range of activities such as global networking opportunities, grant calls for seed grants, training and workshops.

Already, the institutions and industry players within the consortiums are working together. One instance is NTUitive, the commercialisation arm of Nanyang Technological University, which is incubating AdvanceSyn Studio. The latter is a company that does predictive biological engineering.

“We hope to tap onto the interaction platform that the Consortium provides, to further the international partnerships of our technologies and spinoff companies,” says Lim Jui, CEO of NTU Innovation and NTUitive.

NRF previously launched two consortiums, which led to at least six collaborative projects.

sentifi.com

Sentifi - The Edge Markets Singapore - Top themes and market

Ryobi Kiso reverses out the red in FY2017 on absence of one-off losses

SINGAPORE (Aug 23): Ryobi Kiso Holdings posted earnings of $0.8 million for the full year ended June, swinging out from losses of $11.4 million a year ago. This was mainly due to the absence of a one-off items which amounted to other losses of $13.9 million a year ago. These comprised the one-off unrecoverable progress claim of $7.4 million that was written off, and the one-off impairment loss of goodwill of $5.6 million in relation to its Australia subsidiaries in FY2016. Revenue fell 24.2% to $144.8 million in FY2017, from $191.0 million a year ago. Revenue from bored piling operati....
Read More >>

iX Biopharma net losses for FY17 narrow to $7.4 mil

SINGAPORE (Aug 23): iX Biopharma, the specialty pharmaceutical company, reported net losses for FY17 ended June narrowed to $7.4 million from losses of $7.7 million a year ago. Revenue rose 10% to $6.4 million. The group currently derives its main source of revenue from the chemical analysis business which saw an 11% rise to $6.3 million from $5.7 million. Revenue from specialty pharmaceutical fell 52% to $49,000 from $103,000. Despite increased activities, iX Biopharma says expenses remained well-managed. For the full financial year, R&D expenses came in at $4.81 million in FY17 ....
Read More >>

AusGroup says AMJV awarded extension of works on Ichthys Project Onshore LNG Facilities worth $178 mil

SINGAPORE (Aug 23): AusGroup today announced that AMJV has been awarded an extension of works on the INPEX-operated Ichthys LNG Project by JKC Australia LNG worth A$165 million ($177.9 million). See: AusGroup subsidiary wins contract for INPEX-operated Ichthys project AMJV is a joint venture between AGC Industries, a subsidiary of AusGroup, and Meisei Industrial. The scope of work for subcontract that was initially awarded in 2014 has been increased to include further painting, surface protection, fireproofing and insulation works for the onshore facilities near Darwin, Australia. ....
Read More >>